Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK2 | P24941 | 3/20 | 0.56 |
| ▸ | CDK1 | P06493 | 2/20 | 0.56 |
| ▸ | BRD4 | O60885 | 12/20 | 0.55 |
| ▸ | JAK2 | O60674 | 6/20 | 0.55 |
| ▸ | JAK1 | P23458 | 3/20 | 0.55 |
| ▸ | BRDT | Q58F21 | 3/20 | 0.55 |
| ▸ | BRD2 | P25440 | 2/20 | 0.55 |
| ▸ | JAK3 | P52333 | 2/20 | 0.55 |
| ▸ | BRD3 | Q15059 | 2/20 | 0.55 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.54 |
| ▸ | AURKA | O14965 | 1/20 | 0.53 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.53 |
| ▸ | TTK | P33981 | 1/20 | 0.53 |
| ▸ | PLK1 | P53350 | 3/20 | 0.52 |
| ▸ | PRKDC | P78527 | 2/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1782032 | 0.86 | CDK1 (0.68) | CDK2CDK1BRD4JAK2JAK1 | |
| SCHEMBL1781616 | 0.81 | PRKDC (0.49) | CDK2PTK2AURKACCNA2TTK | |
| SCHEMBL1781640 | 0.79 | AURKA (0.69) | CDK2BRD4BRDTPTK2AURKA | |
| SCHEMBL1781666 | 0.79 | TTK (0.60) | CDK2BRD4BRDTPTK2AURKA | |
| SCHEMBL1781331 | 0.76 | CDK4 (0.71) | CDK2CDK1JAK2JAK1JAK3 | |
| SCHEMBL4731427 | 0.76 | PLK1 (0.68) | CDK2CDK1BRD4JAK2JAK1 | |
| SCHEMBL4515808 | 0.76 | BRD4 (0.82) | BRD4BRDTPTK2TTKPLK1 | |
| SCHEMBL1675880 | 0.76 | PLK1 (0.86) | CDK2CDK1BRD4BRDTPLK1 | |
| SCHEMBL1781086 | 0.76 | TTK (0.73) | CDK2AURKACCNA2TTKPRKDC | |
| SCHEMBL1781601 | 0.74 | PRKDC (0.55) | CDK2BRD4AURKACCNA2TTK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-103298814-A | 2-Anilinopurin-8-ones as TTK/MPS1 inhibitors for the treatment of proliferative diseases | ASTRAZENECA AB | 2013-09-11 | — | — | CN | disclosed |
| US-20110118238-A1 | 2-ANILINOPURIN-8-ONES AS INHIBITORS OF TTK/MPS1 FOR THE TREATMENT OF PROLIFERATIVE DISORDERS | ASTRAZENECA AB (SE) | 2011-05-19 | — | — | US | disclosed |
| EP-2212326-A1 | 2-ANILINOPURIN-8-ONES AS INHIBITORS OF TTK/MPS1 FOR THE TREATMENT OF PROLIFERATIVE DISORDERS | AstraZeneca AB (SE) | 2010-08-04 | — | — | EP | disclosed |
| WO-2009024824-A1 | 2-ANILINOPURIN-8-ONES AS INHIBITORS OF TTK/MPS1 FOR THE TREATMENT OF PROLIFERATIVE DISORDERS | ASTRAZENECA AB (SE) | 2009-02-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110118238-A1 | 2-ANILINOPURIN-8-ONES AS INHIBITORS OF TTK/MPS1 FOR THE TREATMENT OF PROLIFERATIVE DISORDERS | BUB1, BUB1B, TTBK1 | CDK2 134/4885CDK1 31/4885BRD4 3407/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.